Thermo Fisher Scientific Introduces the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to Help Advance the Future of Precision Medicine
CGP facilitates the simultaneous analysis of a broad range of biomarkers in one test to maximize insights on the underlying oncogenic drivers in a timely manner. Already available on the Ion GeneStudio™ S5 systems*, the Oncomine Comprehensive Assay Plus detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions. Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB) and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect a broad range of these important biomarkers, quickly and easily.
'We have been waiting for this complete and rapid CGP solution that includes all the relevant biomarkers including TMB, MSI and HRD,' said Hector M Alcaraz, MS, Founder of Imagene Health, SA de CV, an early access user of the Oncomine Comprehensive Assay Plus on the Genexus System. 'This will make CGP more accessible to our local markets so that we can drive the future of precision medicine forward.'
The Genexus System is an automated and integrated NGS platform capable of delivering NGS results as soon as the next day. With end-to-end automation that requires less hands-on time, the Genexus System makes genomic profiling accessible to more researchers with varying levels of experience. Now, with the Oncomine Comprehensive Assay Plus available on the Genexus System, research teams can leverage this end-to-end solution to deliver accurate and robust CGP results as soon as the next day.
'In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development,' said Kathy Davy, president of Clinical Next Generation Sequencing at Thermo Fisher Scientific. 'The addition of the Oncomine Comprehensive Assay Plus on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research.'
For more information about the Oncomine Comprehensive Assay Plus on the Genexus System and how this is enabling research labs to accelerate oncology research, please visit thermofisher.com/oncomine-ocaplus.
*For Research Use Only. Not for use in diagnostic procedures.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 minutes ago
- Business Wire
73% of Rural Healthcare Orgs Say They Struggle to Maintain HIPAA Compliance Due to Staffing and Funding Gaps
SAN FRANCISCO--(BUSINESS WIRE)--As cyber threats grow more frequent and sophisticated, rural hospitals and clinics face challenges on all fronts— tight budgets, limited staff, inadequate training, complex technology, and unsupportive vendors. Many are left trying to manage security tools without the IT resources to support them. 73% of rural healthcare orgs say they struggle to maintain HIPAA compliance due to staffing and funding gaps. Rural healthcare organizations are encountering more roadblocks to cybersecurity than their urban peers—and not just in one or two areas. The findings are part of a broader pattern: rural healthcare organizations are more likely to face every major cybersecurity barrier surveyed, including outdated systems, limited vendor support, and friction-filled tools that hinder care delivery. 'Small and rural hospitals are on the frontline of America's healthcare cybersecurity crisis,' said Doug Brown, founder of Black Book Research. 'The majority lack the staffing, funding, and infrastructure to defend themselves against increasingly sophisticated attacks.' Many rural health systems are operating without the tools or support to safely modernize, while continuing to serve 60 million Americans. As ransomware campaigns and phishing threats continue to rise and become more sophisticated, the tools they rely on—especially for email—are often falling short. 88% of rural leaders said they lack confidence that their current email platform is fully HIPAA compliant out of the box. 'Cyber defense is a moving target, and one that requires significant time, energy and resources,' said Kate Pierce, CIO and CISO at North Country Hospital in Vermont. Among the report's key findings: 73% of rural healthcare orgs say they struggle to maintain HIPAA compliance due to staffing and funding gaps. Rural orgs trail urban ones by 22% in adopting AI-based threat detection. 4 out of 5 rural leaders say their infrastructure can't support advanced email security. 50% say budget limitations are a top barrier to upgrading security tools—nearly double the rate of urban peers. The report also highlights a critical but often overlooked issue: what happens when security tools create friction. According to the survey, 6 out of 10 rural providers say their current secure email platform causes regular complaints and workflow delays. More than half report poor mobile usability and slow encryption that can delay care. 'We can't expect rural hospitals to meet the same compliance standards as large systems without giving them tools that fit their size and structure,' said Rick Kuawahara, Chief Compliance Officer at Paubox, 'In cybersecurity, usability is security.' When tools get in the way, staff start looking for workarounds—like reverting to personal email, skipping encryption steps, or delaying communication altogether. The report calls for secure communication tools that are built for lean teams, designed to run quietly in the background. To see the full data and recommendations, read the report: Rural Healthcare Left Vulnerable to Cyber Attacks. About Paubox
Business Wire
38 minutes ago
- Business Wire
Muncy Columbia Financial Corporation Announces Second Quarter 2025 Earnings
BLOOMSBURG, Pa.--(BUSINESS WIRE)--Muncy Columbia Financial Corporation ('Corporation') (OTCQX: CCFN), parent company of Journey Bank ('Bank'), has released its unaudited consolidated financial results for the second quarter of 2025. Net income, as reported under accounting principles generally accepted in the United States of America ('GAAP'), for the second quarter 2025 was $5,768,000, or $1.63 per share, compared to $4,707,000, or $1.32 per share, for the second quarter 2024. Net income, as reported under GAAP, for the six months ended June 30, 2025 was $10,113,000, or $2.86 per share compared to $8,743,000, or $2.45 per share for the same period in 2024. Return on average assets and return on average equity were 1.44% and 13.33%, respectively, for the second quarter 2025 as compared to 1.20% and 12.28%, respectively, for the second quarter 2024. Net interest income of $14,808,000 for the second quarter 2025 was up $2,448,000 from the second quarter 2024 reflecting an increase in total interest and dividend income of $1,467,000 and a decrease of $981,000 in total interest expense. The fully-tax equivalent net interest margin was 4.04% for the second quarter 2025 as compared to 3.43% for the second quarter 2024. For the second quarter 2025, a $254,000 provision for credit losses was recorded compared to $29,000 for the second quarter 2024. As of June 30, 2025 and December 31, 2024, the allowance for credit losses to total loans was 0.88%. Total non-interest income decreased $182,000 to $2,237,000 for the second quarter 2025, compared to the second quarter 2024 amount of $2,419,000. Realized losses on available-for-sale debt securities, net, totaled $426,000 for the second quarter 2025 compared to $0 for the second quarter 2024. This change was partially offset by increases in brokerage income and trust income of $60,000 and $76,000, respectively, due primarily to higher assets under management, and an increase in gains on marketable equity securities of $52,000 due to market value changes comparing the second quarter 2025 to the second quarter 2024. Total non-interest expense increased $662,000 from $9,194,000 for the second quarter 2024, to $9,856,000 for the second quarter 2025. Salaries and employee benefits expense of $4,984,000 for the second quarter 2025 increased $344,000 from $4,640,000 for the second quarter 2024. This increase was related to health insurance expenses associated with the Corporation's partially self-funded health insurance plan which were $397,000 higher in the second quarter 2025 than the second quarter 2024. Additionally, data processing and telecommunications expenses increased $174,000 comparing the second quarter 2025 to the second quarter 2024 due to ongoing pricing increases and one-time charges in conjunction with the implementation of new products. Total assets amounted to $1,616,215,000 at June 30, 2025, as compared to $1,595,958,000 at December 31, 2024. For the six months ended June 30, 2025, cash and cash equivalents increased $23,332,000, available-for-sale debt securities decreased $30,484,000 and loans receivable, not held for sale, increased by $31,135,000. Total liabilities amounted to $1,439,940,000 at June 30, 2025, as compared to $1,429,548,000 at December 31, 2024. Total deposits increased $68,634,000 while short-term borrowings decreased $50,267,000 and long-term borrowings decreased $10,085,000 during the six months ended June 30, 2025. The increase in total deposits during the six months ended June 30, 2025 was as a result of strong organic deposit growth in combination with the continued execution of a strategic initiative to reposition customer repurchase agreements, which are classified as short-term borrowings, into core deposit accounts. The Bank anticipates the completion of this project later in 2025 which will assist in optimizing the Bank's long-term liquidity needs and balance sheet management strategies. Total non-performing assets amounted to $13,844,000 or 0.86% of total assets at June 30, 2025, as compared to $10,117,000 or 0.63% of total assets at December 31, 2024. The increase in non-performing assets was attributable to an increase in non-accrual loans from $10,047,000 at December 31, 2024 to $13,774,000 at June 30, 2025. Total stockholders' equity equated to a book value per share of $49.87 at June 30, 2025 as compared with $47.11 at December 31, 2024. For the second quarter 2025 total cash dividends of $0.95 per share were paid to stockholders, which includes the impact of a special one-time cash dividend of $0.50 per share, as compared to $0.44 for the same period of 2024. The Corporation remains well capitalized, with an equity to assets ratio of 10.91% at June 30, 2025 as compared to 10.43% at December 31, 2024. About Muncy Columbia Financial Corporation Muncy Columbia Financial Corporation ("MCFC") is a registered financial holding company headquartered in Bloomsburg, Pennsylvania. MCFC has one subsidiary bank, Journey Bank, serving individuals, families, nonprofits and business clients throughout Clinton, Columbia, Lycoming, Montour, Northumberland and Sullivan Counties through 22 banking offices. Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of current or historical fact and involve substantial risks and uncertainties. Words such as "anticipates," "believes," "estimates," "expects," "forecasts," "intends," "plans," "projects," "may," "will," "should," and other similar expressions can be used to identify forward-looking statements. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. Among the risks and uncertainties that could cause actual results to differ from those described in the forward-looking statements include, but are not limited to the following: changes in general economic trends, including inflation and changes in interest rates; our ability to manage credit risk; our ability to maintain an adequate level of allowance for credit loss on loans; increased competition; changes in consumer demand for financial services; our ability to control costs and expenses; fluctuations in the values of securities held in our securities portfolio, including as a result of changes in interest rates; our ability to successfully manage liquidity risk; adverse developments in borrower industries and, in particular, declines in real estate values; the concentration of large deposits from certain customers who have balances above current FDIC insurance limits; changes in and compliance with federal and state laws that regulate our business and capital levels; our ability to raise capital as needed; and any other risks described in the 'Risk Factors' sections of reports filed by the Corporation with the Securities and Exchange Commission. We do not undertake, and specifically disclaim, any obligation to publicly revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements, except as required by law. Accordingly, you should not place undue reliance on forward-looking statements. Muncy Columbia Financial Corporation Consolidated Statements of Income For the Three Months Ended For the Six Months Ended June 30, June 30, (In Thousands, Except Share and Per Share Data) (Unaudited) 2025 2024 2025 2024 INTEREST AND DIVIDEND INCOME Interest and fees on loans: Taxable $ 18,805 $ 17,741 $ 37,089 $ 34,997 Tax-exempt 420 332 818 685 Interest and dividends on investment securities: Taxable 1,311 1,020 2,408 2,181 Tax-exempt 860 836 1,720 1,666 Dividend and other interest income 165 204 333 427 Deposits in other banks 101 62 135 128 TOTAL INTEREST AND DIVIDEND INCOME 21,662 20,195 42,503 40,084 INTEREST EXPENSE Deposits 6,037 5,610 11,838 10,220 Short-term borrowings 252 1,427 795 3,924 Long-term borrowings 565 798 1,194 1,645 TOTAL INTEREST EXPENSE 6,854 7,835 13,827 15,789 NET INTEREST INCOME 14,808 12,360 28,676 24,295 PROVISION FOR CREDIT LOSSES 254 29 364 119 NET INTEREST INCOME AFTER PROVISION FOR CREDIT LOSSES 14,554 12,331 28,312 24,176 NON-INTEREST INCOME Service charges and fees 709 667 1,431 1,282 Interchange fees 673 687 1,296 1,306 Gain on sale of loans 71 93 154 169 Earnings on bank-owned life insurance 233 229 464 456 Brokerage 252 192 485 416 Trust 280 204 518 410 Gains (losses) on marketable equity securities 14 (38 ) (20 ) (155 ) Realized losses on available-for-sale debt securities, net (426 ) - (426 ) (8 ) Other non-interest income 431 385 780 1,075 TOTAL NON-INTEREST INCOME 2,237 2,419 4,682 4,951 NON-INTEREST EXPENSE Salaries and employee benefits 4,984 4,640 11,304 9,442 Occupancy 640 581 1,360 1,199 Furniture and equipment 460 384 886 790 Pennsylvania shares tax 301 230 602 440 Professional fees 414 319 862 776 Director's fees 165 105 318 239 Federal deposit insurance 217 188 435 408 Data processing and telecommunications 1,078 904 1,917 1,824 Automated teller machine and interchange 101 106 365 368 Merger-related expenses - 201 - 297 Amortization of intangibles 516 549 1,026 1,098 Other non-interest expense 980 987 1,872 1,959 TOTAL NON-INTEREST EXPENSE 9,856 9,194 20,947 18,840 INCOME BEFORE INCOME TAX PROVISION 6,935 5,556 12,047 10,287 INCOME TAX PROVISION 1,167 849 1,934 1,544 NET INCOME $ 5,768 $ 4,707 $ 10,113 $ 8,743 EARNINGS PER SHARE - BASIC AND DILUTED $ 1.63 $ 1.32 $ 2.86 $ 2.45 WEIGHTED AVERAGE SHARES OUTSTANDING 3,533,977 3,572,345 3,533,356 3,571,344 Expand At or 3 Months Ended (Unaudited) (Dollars in Thousands, Except Per Share Data) 6/30/2025 3/31/2025 12/31/2024 9/30/2024 6/30/2024 Operating Highlights Net income $ 5,768 $ 4,345 $ 5,224 $ 5,056 $ 4,707 Net interest income 14,808 13,868 13,396 12,774 12,360 Provision for credit losses 254 110 567 151 29 Non-interest income 2,237 2,445 2,709 2,715 2,419 Non-interest expense 9,856 11,091 9,455 9,367 9,194 Balance Sheet Highlights Total assets $ 1,616,215 $ 1,602,336 $ 1,595,958 $ 1,607,322 $ 1,592,300 Loans, net and loans held for sale 1,149,624 1,135,981 1,117,770 1,105,421 1,092,057 Goodwill and other intangibles, net 34,653 35,164 35,656 36,202 36,760 Total deposits Noninterest-bearing $ 272,680 $ 273,783 $ 259,700 $ 269,515 $ 263,419 Savings 194,816 195,748 194,958 192,644 199,626 NOW 422,415 406,330 380,801 364,459 346,000 Money Market 104,677 103,759 108,263 112,319 117,770 Time Deposits 366,475 359,015 348,707 351,532 338,812 Total interest-bearing deposits 1,088,383 1,064,852 1,032,729 1,020,954 1,002,208 Core deposits* 994,588 979,620 943,722 938,937 926,815 Selected Ratios Fully tax-equivalent net interest margin 4.04 % 3.83 % 3.63 % 3.48 % 3.43 % Annualized return on average assets 1.44 % 1.10 % 1.30 % 1.26 % 1.20 % Annualized return on average equity 13.33 % 10.33 % 12.30 % 12.34 % 12.28 % Capital Ratios - Journey Bank** Common equity tier I capital ratio 15.35 % 15.13 % 15.06 % 14.59 % 14.06 % Tier 1 capital ratio 15.35 % 15.13 % 15.06 % 14.59 % 14.06 % Total risk-based capital ratio 16.34 % 16.13 % 16.03 % 15.54 % 14.99 % Leverage ratio 9.43 % 9.30 % 9.10 % 8.82 % 8.68 % Asset Quality Ratios Non-performing assets $ 13,844 $ 12,300 $ 10,117 $ 8,575 $ 7,736 Allowance for credit losses - loans 10,167 9,985 9,858 9,415 9,362 Allowance for credit losses to total loans 0.88 % 0.87 % 0.88 % 0.85 % 0.85 % Non-performing assets to total assets 0.86 % 0.77 % 0.63 % 0.53 % 0.49 % Per Share Data Earnings per share $ 1.63 $ 1.23 $ 1.47 $ 1.42 $ 1.32 Dividend declared per share*** 0.95 0.45 0.44 0.44 0.44 Book value 49.87 48.50 47.11 47.35 44.11 Common stock price: Bid $ 47.25 $ 40.25 $ 41.88 $ 33.35 $ 32.10 Ask 49.05 42.00 42.88 34.25 34.75 Weighted average common shares 3,533,977 3,532,727 3,555,920 3,574,043 3,572,345 * Core deposits are defined as total deposits less time deposits ** Capital ratios for the most recent period are estimated *** Includes special one-time cash dividend of $0.50 per share for the three months ended 6/30/2025 Expand
Business Wire
38 minutes ago
- Business Wire
CRC Group Unveils Luxury Residential Greater Noida Project in Dubai
DUBAI, United Arab Emirates & NOIDA, India--(BUSINESS WIRE)--CRC Group, a leading player in North India's real estate sector, has unveiled its uber ultra-luxury experiential residential development, The PERIDONA, located within Jaypee Greens Golf Course in Greater Noida. With a development outlay of Rs15 billion (exclusive of land cost), the project signals CRC's strategic intent to elevate its portfolio into the ultra-premium segment. Spanning a total built-up area of 3.1 million sq. ft., the project will comprise 341 apartments. Unveiled during a marquee event in Dubai, The PERIDONA brings together an extraordinary lineup of design and architecture consultants: Killa Design, renowned for crafting Dubai's Museum of the Future; Rockwell Group, the New York-based interior visionaries behind one of Gurugram's most iconic luxury clubs; Gensler Architects, global leaders in progressive, future-ready architectural design; SWA Group, experts in sustainable landscape architecture; and MACE, a global firm specializing in precision project management and execution. Kunal Bhalla, Founder & CEO, CRC Group, commented, 'The PERIDONA marks our strategic entry into India's ultra-luxury residential space. Supported by world-class design and architecture, this development reflects our clear ambition to set a new benchmark for premium living in the NCR. The project is envisioned to establish an international standard in luxury condominiums, with a strong focus on sustainable, high-quality living. We have carefully selected best-in-class materials and curated exceptional amenities—many being introduced in India for the first time—to deliver a truly exalted lifestyle. The core philosophy driving the project is simple yet powerful: 'Live More,' with abundant amenities that define a luxurious way of life.' Salil Kumar, Director (Marketing & Business Management), CRC Group, said: 'This project is a testimony to our commitment to global standards. The PERIDONA also enjoys a distinct locational advantage with expansive green surroundings, enhancing both aesthetics and liveability. With just one apartment per floor, the project offers an unmatched level of privacy—an essential attribute in modern luxury living.' Construction is slated to commence next month. With the upcoming Noida International Airport—set to become the world's fourth-largest—just a 20-minute drive away, The PERIDONA enjoys a locational edge. This proximity not only enhances the project's connectivity and prestige but also positions it as a high-potential asset for long-term value appreciation and strong return on investment.
